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Abstract
Results from our laboratory have suggested a pathway involving angiotensin II type 1 (AT1)
receptors and vascular endothelial growth factor (VEGF) in angiogenesis induced by electrical
stimulation. The present study investigated if similar mechanisms underlie the angiogenesis
induced by short-term exercise training. Seven days before training and throughout the training

period, male Sprague-Dawley rats received either captopril or losartan in their drinking water.
Rats underwent a 3-day treadmill training protocol. The tibialis anterior and gastrocnemius
muscles were harvested under anesthesia and lightly fixed in formalin (vessel density) or
frozen in liquid nitrogen (VEGF expression). In controls, treadmill training resulted in a
significant increase in vessel density in all muscles studied. However, the angiogenesis
induced by exercise was completely blocked by either losartan or captopril. Western blot
analysis showed that VEGF expression was increased in the exercised control group, and both
losartan and captopril blocked this increase. The role of VEGF was directly confirmed using a
VEGF-neutralizing antibody. These results confirm the role of angiotensin II and VEGF in
angiogenesis induced by exercise.
regular aerobic exercise training can induce a series of adaptive responses in cardiovascular
and skeletal systems. The adaptations of skeletal muscle include increases in the oxidative
enzyme activity as well as the number and size of mitochondria. Skeletal muscle angiogenesis,
determined by an increase in capillary density and/or capillary-to-fiber ratio, reflects a vital
adaptation to exercise, contributing to the improved aerobic capacity (O2transport, O2
conductance, and O2 extraction) of skeletal muscle. Although most of these results have been
described after a long period of endurance training, results from our laboratory have suggested
the possibility that the microcirculation of skeletal muscle can adapt and change structure very
rapidly after exercise or electrical stimulation (2, 23, 26). The mechanisms underlying the capillary
growth process in skeletal muscle are not yet understood. Different angiogenic factors have
been characterized, and much attention has focused on vascular endothelial growth factor
(VEGF). Several lines of evidence indicate that VEGF is involved in the regulation of the
angiogenic process in vitro (25, 37) and in vivo (2, 8, 9, 19, 21, 29, 36). Accordingly, an elevation of
VEGF mRNA has been reported in skeletal muscle after a single bout of exercise in rats (5, 11,
12) and humans (18, 28, 29). These studies suggest that the microcirculation of skeletal muscle is
likely to respond in a more dynamic fashion than previously considered and may play an
important role in short-term adaptations to exercise. Recently, results from our laboratory (2)
have suggested a pathway involving angiotensin II (ANG II) type 1 (AT1) receptors and VEGF
protein expression in angiogenesis induced by electrical stimulation. The present study
investigated if these mechanisms underlie the angiogenesis induced by short-term exercise
training.

METHODS
The Institutional Animal Care Committee at the Medical College of Wisconsin and Marquette
University approved all protocols and procedures. Seventy-four male Sprague-Dawley rats (8–
9 wk old) were familiarized with treadmill running for 4 days before the beginning of training.
This preliminary exercise was limited to 5–10 min. All animals were fed a standard laboratory
rat chow (Purina) and water ad libitum. All animals were housed in single cages to permit
assurance of proper daily fluid intake.

Drugs
Captopril was obtained from Sigma (St. Louis, MO), losartan was obtained from Merck (West
Point, PA), and monoclonal VEGF-neutralizing antibody was generously provided by Texas
Biotechnology (Houston, TX).

Experimental Design
After familiarization, age- and weight-matched rats were randomly assigned to the following
four experimental protocols:

Experiment 1.
Eight rats were given water during the entire exercise protocol.

Experiment 2.
Eight rats were given captopril (100 mg · kg−1 · day−1) in their drinking water 7 days before and
during the entire exercise protocol.

Experiment 3.
Eight rats were given losartan (50 mg/day) in their drinking water 7 days before and during the
entire exercise protocol.

Experiment 4.
Thirteen rats were given VEGF-neutralizing antibody (0.6 mg/100 g ip) or PBS (control) 1 day
before and the following 2 days of the exercise protocol.
Additionally, 8 animals receiving water, 8 animals receiving captopril, 8 animals receiving
losartan, and 13 animals receiving VEGF-neutralizing antibody or PBS were used as
sedentary controls.

Training Protocol
All rats were assigned to run on a treadmill at 20 m/min, 5% grade, for 1 h/day for 3 days.
Exercise began daily at 9:00 AM and was repeated for 3 consecutive days. Groups were
randomly placed on the treadmill each day. After the last training period, all animals were
anesthetized with pentobarbital sodium within 2 h of exercising (5). The hindlimb muscles were
removed, and the animals were euthanized.

Surgical Catheter Implantation and Acute Arterial Pressure Measurements in Rats Treated
With Captopril
After 10 days of drug treatment, rats (n = 4) were anesthetized with pentobarbitol sodium (50
mg/kg ip), a polyvinyl catheter was placed in the right carotid artery and right jugular vein, and
blood pressure (BP) was measured for at least 15 min. The effectiveness of chronic inhibition
of angiotensin-converting enzyme (ACE) by oral captopril was determined by recording the
changes in arterial pressure induced by an intravenous bolus of angiotensin I (ANG I; 0.1 ml at
1 ng/ml iv). The effectiveness of chronic blockade of AT1 receptors by oral losartan was
previously determined by an intravenous bolus of ANG II (2).

Tissue Harvest and Morphological Analysis of Vessel Density
After 3 days of exercise training, the animals were euthanized by an overdose of Beuthanasia
solution (Sigma). The gastrocnemius (GA) and tibialis anterior (TA) muscles were removed,
rinsed in physiological saline solution (PSS), and weighed. The GA was then separated into
white (GAW) and red (GAR) parts. The separation of the red from the white muscle was
performed after the whole GA muscle was harvested from the leg. The muscle was opened
with a delicate scissor, and the red portion was removed from the white part of the GA muscle.
A 100-mg section was taken from each muscle and immediately frozen in liquid nitrogen for
Western blot analysis. The remaining tissues were lightly fixed overnight in 0.25% formalin
solution. The fixed muscles were sectioned as previously described (22). From every animal,
two slices of each muscle were made and immersed in a solution of 25 μg/ml rhodaminelabeled Griffonia simplicifolia I(GS-I) lectin (Sigma). After the 2-h exposure to GS-I lectin, the
muscles were rinsed and mounted on microscope slides in a water-soluble mounting medium
consisting of toluene and acrylic resin (SP ACCU-MOUNT 280, Baxter Scientific; McGaw Park,
IL) (13).
The sections were visualized using a video fluorescent microscope system with epi-illumination
(Olympus ULWD CD Plan, ×20 objective). Ten representative fields were selected for study
from each muscle slice. Images were digitized and quantified with automated computer vessel
counting as previously described (30).

Western Blot Analysis to Detect the Presence of VEGF Protein
One hundred milligrams of each muscle specimen were homogenized, and the protein was
suspended in potassium buffer (10 mM). Five micrograms of protein (as determined by protein
assay kit, Bio-Rad; Hercules, CA) from each muscle and a tumor cell line known to express
VEGF at high levels (C6, American Type Culture Collection, 107-CCL) were separated on a
12% denaturing polyacrylamide gel. The gels were transferred to a nitrocellulose membrane,
which was blocked for 2 h at room temperature in 5% nonfat dry milk diluted in Tris-buffered
saline (50 mM Tris and 750 mM NaCl; pH = 8) with 0.08% Tween 20 (Bio-Rad). The blots were
then incubated overnight with a polyclonal antibody to a peptide derived from the human VEGF
sequence (1:1,000 dilution, clone G143-850, Pharmingen). Washed blots were then incubated
with goat anti-mouse secondary antibody at a dilution of 1:1,000 for 1 h at room temperature

and then subjected to the SuperSignal West Dura chemiluminescence substrate (Pierce;
Rockford, IL) detection system. Membranes were exposed to X-ray film (Fuji Medical;
Stamford, CT) for 30∼60 s and developed using a Kodak M35 X-Omat processor. For the
quantitative VEGF analysis, film was always exposed for a period of time that ensured that all
signals were within the linear range of the detection of the film. The VEGF band intensity was
quantified using a Morphometry Imaging System (Metamorph, Universal Imaging), and values
are expressed as a percentage of the C6 tumor cell standard.

VEGF-Neutralizing Antibody to Confirm the Role of VEGF in Angiogenesis
To determine whether VEGF was essential to angiogenesis induced by short-term exercise
training, we conducted an additional protocol using two groups of rats (7 wk). Three doses of
monoclonal VEGF-neutralizing antibody (Texas Biotechnology) were administered during the
period of exercise training. The protocol for administration of VEGF-neutralizing antibody was
modified from Zheng et al. (36), and the dose was based on our previous results (2). One day
before the exercise protocol, 0.6 mg/100 g antibody was injected intraperitoneally in all rats.
Just before the exercise was started, the rats received intraperitoneal injections ondays 1 and
2. All rats were euthanized onday 3, within 2 h after the treadmill training was completed.

Data Analysis and Statistics
For each muscle, the vessel counts of all the selected fields (10 scans × 2 slices for each
muscle) were averaged to a single vessel density. Vessel density was expressed in terms of
mean number of vessel-grid intersections per microscope field (0.224 mm2). For each
experimental group, the measured vessel density of the muscles was compared with the same
muscle from sedentary group. All values are presented as means ± SE. The significance of
differences in values measured in all groups was evaluated using a two-factor ANOVA (drug ×
condition). Significant differences were further investigated using a post hoc test (Tukey's).

RESULTS
Table 1 summarizes the body weights and muscle-to-body weight ratios of the control
sedentary and exercised rats, those treated with captopril or losartan and also those treated
with VEGF-neutralizing antibody. All rats were the same age (9 wk old) at the start of the
experiments, and there were no significant effects of drug on body or muscle weights.
Although body weight increased after 3 days of exercise, the muscle weights of all animals
analyzed were not different.
Table 1. Body weights and GA and TA muscle weight-to-body weight ratios of exercised and
sedentary rats
Groups
Control exercise

n
8

Body Weight
Start weight

End weight

249.0 ± 5.4

287.9 ± 3.5*

GA/Body Weight

TA/Body Weight

0.52 ± 0.03

0.20 ± 0.01

Groups

n

Body Weight
Start weight

End weight

GA/Body Weight

TA/Body Weight

Control sedentary

8

248.1 ± 4.6

277.9 ± 7.1*

0.57 ± 0.01

0.21 ± 0.01

Captopril exercise

8

249.8 ± 4.6

275.4 ± 3.3

*

0.52 ± 0.04

0.20 ± 0.01

Captopril sedentary

8

246.5 ± 3.1

279.6 ± 2.8

*

0.57 ± 0.01

0.21 ± 0.01

Losartan exercise

8

246.1 ± 5.0

278.5 ± 2.7*

0.57 ± 0.02

0.21 ± 0.01

Losartan sedentary

8

248.5 ± 6.3

283.8 ± 5.5

*

0.56 ± 0.01

0.20 ± 0.01

Control (PBS) exercise

7

251.1 ± 7.34

258.9 ± 6.9

*

0.55 ± 0.01

0.20 ± 0.01

Control (PBS) sedentary

7

233.3 ± 11.3

249.3 ± 12.8*

0.51 ± 0.01

0.19 ± 0.01

VEGF Ab exercise

6

223.8 ± 1.7

233.3 ± 1.5

*

0.52 ± 0.01

0.20 ± 0.01

VEGF Ab sedentary

6

229.2 ± 3.6

247.8 ± 3.7*

0.53 ± 0.01

0.19 ± 0.01

Values are means ± SE; n = number of muscles in each group. Body weights are given in grams; muscle weights
are given in milligrams per kilogram. GA, gastrocnemius muscle; TA, tibialis anterior muscle; Ab, vascular
endothelial growth factor (VEGF)-neutralizing antibody.
*
Significant versus before exercise, P < 0.05.

The effectiveness of the oral captopril dose used was determined by assessing the change in
mean arterial pressure in response to a bolus dose of ANG I. There was a significant increase
in mean arterial pressure (51 ± 9 mmHg) after an acute bolus of ANG I in the control group
(data not shown). In contrast, the increase of the mean arterial pressure of animals treated
with captopril (20 ± 3 mmHg) was significantly lower compared with that of control animals.
A significant increase in the vessel density of the control group was observed after 3 days of
running in all muscles analyzed. As shown in Fig. 1, vessel density was increased by 23% in
TA muscle (P < 0.05). The increase of vessel density of TA muscle was completely blocked
after 10 days of oral treatment with captopril (−0.68 ± 1.54%, P < 0.05) or losartan (0.33 ±
2.49%, P < 0.05). Figure 2 shows that vessel density in GAW muscle was increased after 3
days of exercise on treadmill (23%,P < 0.05). Captopril and losartan also inhibited the
increases in vessel density in GAW muscle (0.4 ± 2.88 and 0.82 ± 2.03% for captopril and
losartan, respectively,P > 0.05). In the GAR muscle (Fig.3), exercise caused an increase of
16% in vessel density (P < 0.05). Both captopril and losartan blocked this response (−1.47 ±
5.55 and −0.48 ± 2.02% for captopril and losartan, respectively, P < 0.05)

Fig. 1. Change in vessel density of the tibialis anterior (TA) muscle in sedentary (n = 8) and exercisetrained rats (n = 8) and those treated for 10 days with captopril (100 mg · kg−1 · day−1,n = 16) and
losartan (50 mg/day, n = 16) after 3 days of exercise training. *Significance vs. sedentary rat,P < 0.05.

Fig. 2. Change in vessel density of the white part of the gastrocnemius (GAW) muscle in sedentary (n =
8) and exercise-trained rats (n = 8) and those treated for 10 days with captopril (100 mg · kg−1 · day−1,n
= 16) and losartan (50 mg/day, n = 16) after 3 days of exercise training. *Significance vs. sedentary
rat,P < 0.05.

Fig. 3. Change in vessel density of the red part of the gastrocnemius (GAR) muscle in sedentary (n =
8) and exercise-trained rats (n = 8) and those treated for 10 days with captopril (100 mg · kg−1 · day−1,n
= 16) and losartan (50 mg/day, n = 16) after 3 days of exercise training. *Significance vs. sedentary rat,
P < 0.05.

Western blot analysis and quantitative densitometry were used compare the responses of
VEGF expression in the skeletal muscle after 3 days of exercise in all groups of animals
(Fig.4). VEGF protein levels were significantly increased by 3 days of exercise in control
animals in all muscles analyzed (P < 0.05). This response was completely blocked or strongly
attenuated by both captopril and losartan in all muscles studied.

Fig. 4. Quantitative densitometry of vascular endothelial growth factor (VEGF) protein in three different
groups of rats: control (TA,n = 10; GAW, n = 12; GAR,n = 11), captopril treated (TA, n = 13; GAW, n =
13; GAR, n = 10), and losartan treated (TA, n = 13; GAW, n = 10; GAR,n = 12). Values are expressed
as a percentage of control (C6 tumor cells). *Significance vs. sedentary, P < 0.05.

To evaluate the role of VEGF in the angiogenic response, a group of rats was administered a
monoclonal VEGF-neutralizing antibody during the exercise period. As shown in Fig. 5, the
angiogenesis induced by exercise training was completely blocked in all muscles analyzed
(sedentary + Ab vs. trained + Ab groups) after chronic treatment with a high dose of VEGFneutralizing antibody when compared with trained rats treated with PBS (trained + PBS).

Fig. 5. Vessel density changes in skeletal muscle after 3 days of exercise training associated with
treatment with monoclonal VEGF-neutralizing antibody (Ab). TA, GAW, and GAR muscles of control
rats (PBS treated, n = 7 sedentary and 7 trained) and those treated with monoclonal VEGF-neutralizing
antibody (0.6 mg/kg 1 day before the protocol and on days 1 and 2,n = 6 sedentary and 6 trained) are
shown. *Significance vs. sedentary rats.

DISCUSSION
The main finding of this study is that 3 days of aerobic exercise training significantly increased
vessel density of both GAW and GAR muscles as well as TA muscle compared with sedentary
control animals. Neither captopril nor losartan had any effect on vessel density or VEGF
expression in sedentary rats. However, the drugs (captopril or losartan) blocked VEGF protein
expression and the angiogenesis induced by short-term exercise training.
Increases in capillary density represent an essential adaptive response of skeletal muscle to
repeated exercise, causing an increase in the number of capillaries per muscle fiber, which
enhances O2transport conductance between the microcirculation and mitochondria. It is well
known that physiological angiogenesis is a compensatory response to prolonged imbalances
between the metabolic requirements of the tissue and the perfusion capabilities of the
vasculature (1). The mechanisms underlying the capillary growth process remain unknown. It is
likely that a variety of factors are required to initiate physiological angiogenesis in response to
exercise. On the basis of previous work (3, 21) in vitro and in vivo, reduced O2 tension as well as
growth factors, hormones, and mechanical factors have been proposed to be important in the
angiogenesis process in cardiac and skeletal muscle.
The extensive literature relating VEGF to vessel growth provides strong evidence that VEGF
promotes angiogenesis in many tissues and under different conditions. VEGF, also known as
vascular permeability factor, is the most potent and direct angiogenic factor known in vitro and
in vivo (8, 10) with some specificity for vascular endothelial cells (22). Recent work from our
laboratory (2) has shown that VEGF is partially responsible for the angiogenesis induced by

electrical stimulation in skeletal muscle. Results from the present study showed that only 3
days of exercise can cause increases in VEGF protein expression. Increases in VEGF mRNA
have been shown as a consequence of electrical stimulation (3,19) and exercise (5, 11, 12, 18, 28, 29).
Breen et al. (5) have shown that mRNA of angiogenic factors in skeletal muscle [VEGF, basic
fibroblast growth factor (bFGF), and transforming growth factor (TGF)-β1] increased after 1 h of
exercise in intact animals. Accordingly, Richardson et al. (28) and Gustafsson et al. (18) found
increases in VEGF (but not in TGF-β or bFGF) mRNA after 45–60 min of leg-knee extensor
exercise in humans; however, these changes in mRNA were not necessarily accompanied by
changes in protein. It seems that VEGF may be involved in the early process of angiogenesis
induced by exercise, because, after long periods of training, the amount of VEGF gene
expression induced by exercise is attenuated (29). Because VEGF is upregulated after electrical
stimulation and exercise, it has been considered a potent angiogenic factor; however, there is
only one report (29) that measured both increases in VEGF gene expression and vessel
density. The present study is the first to indicate that 3 days of exercise increases VEGF
protein expression in skeletal muscle, with a consequent increase in capillary density. The
present results also demonstrate that treatment with VEGF-neutralizing antibody completely
blocked the angiogenesis induced by exercise compared with control groups. These
responses, together with our previous results (2), provide strong support for the hypothesis that
VEGF plays an important role in the angiogenesis induced by exercise. The results of the
present work also suggest that angiogenesis may precede the changes in oxidative proteins,
suggesting that the microvasculature of skeletal muscle is capable of undergoing rapid
remodeling in response to exercise. This rapid increase in vessel density may account for the
short-term (7 days) training effects previously reported when oxidative enzyme content is as
yet unchanged (27).
The mechanisms underlying the change in VEGF expression as well as the capillary growth
process are still unclear. Local hypoxia may be postulated as a trigger of increases in VEGF
and angiogenesis induced by exercise. Although some experiments (4, 5, 15, 17, 18, 28,33) in vitro
and in vivo have shown increases in VEGF under hypoxic conditions, the role of hypoxia in
increasing VEGF mRNA during exercise is not completely understood. Breen et al. (5) showed
that 1 h of exercise or hypoxia itself can independently increase VEGF gene expression in
skeletal muscle and that the increase in expression was greater when the exercise was done
under hypoxic conditions. More recently, Gustafsson et al. (18) found decreases in the Po2 in
working muscles after 30–45 min of leg-knee extension. This study also showed a correlation
between increases in VEGF gene expression and increases in hypoxia-inducible factor mRNA.
Conversely, Richardson et al. (28), using the same protocol of exercise (leg-knee extension),
failed to demonstrate a correlation between cell Po2 and VEGF mRNA. In that study (28), the
increases in VEGF gene expression were of the same magnitude when the exercise was done
in normoxic or hypoxic conditions. Some biomechanical events, such as shear stress, capillary
wall tension, or vascular stretch, have been considered possible inducers of VEGF expression
(21); however, these hypotheses remain unclear. While it has been shown that increases in
blood flow can be responsible for releasing growth factors, Roca et al. (31) failed to demonstrate
increases in VEGF mRNA expression in skeletal muscle of dogs during passive
hyperperfusion. On the other hand, a recent report (37) showed that stretch induces VEGF gene
expression and protein upregulation in coronary microvascular endothelial cells and cardiac
myocytes in vitro. During exercise, high quantities of ATP are consumed, releasing inorganic

phosphate and contributing to increases in ADP and AMP, thus increasing levels of adenosine.
Adenosine is a purine nucleoside composed of adenine and ribose joined by a glycosidic bond.
Some evidence has shown that adenosine can be modulated by hypoxia (20) when the
metabolic rate increases (14), stimulating endothelial proliferation in vitro as well as growth of
blood vessels in in vivo models. These characteristics suggest an important regulatory role of
adenosine in VEGF expression and consequently in angiogenesis. Recent evidence has
shown that adenosine could increase VEGF mRNA in cultured cells (16, 17). Accordingly, Fischer
et al. (10) reported that one inhibitor of cAMP phosphodiesterase (rolipram) completely blocked
the upregulation of VEGF mRNA induced by adenosine. Results from Gu et al. (15) suggested
that adenosine (acting by VEGF) can be considered as a maintenance factor for the
vasculature, responsible for balancing the size of the capillary network according to the
metabolic rate.
An interaction between the renin-angiotensin system (RAS), VEGF, and consequently
angiogenesis has been suggested previously (6, 7,24, 35). Results from our laboratory have
shown that infusion of ANG II increases vessel density in skeletal muscle (24). Williams et al. (35)
demonstrated that ANG II significantly increased VEGF gene expression, suggesting that
besides changes in hemodynamics, ANG II could locally influence permeability and growth in
the vascular endothelium. More recently, Chua et al. (6) demonstrated that ANG II was able to
efficiently upregulate VEGF expression in cultured cells.
Otani et al. (25) showed that ANG II itself cannot increase either VEGF gene expression or cell
proliferation; however, it can potentiate VEGF-dependent cell proliferation and tube formation
of retinal microvascular endothelial cells through induction of the VEGF receptor KDR/Flk-1.
Results from our laboratory (2) have suggested that the RAS is involved in VEGF protein
expression and angiogenesis induced by electrical stimulation. The present study
demonstrates that the induction of VEGF protein by exercise can also be modulated by the
RAS, because treatment with captopril or losartan completely blocked the increased
expression of VEGF.
The effects of ACE inhibitors on the growth pathway have been described in both in vitro and
in vivo studies. Volpert et al. (34) showed that captopril inhibited bFGF-induced corneal
neovascularization in female rats. This study also demonstrated that captopril inhibited cell
migration in vitro. More recently, Gavin et al. (11) showed that the 4.8-fold increase in VEGF
gene expression induced by exercise was not attenuated by acute injection of captopril;
however, the drug decreased the expression of mRNA for the VEGF receptor KDR/Flk-1 but
not Flt-1. Because KDR/Flk-1 is the VEGF receptor responsible for vasculogenesis (8, 9), this
result agrees with the hypothesis that captopril can decrease vessel density induced by
exercise. In agreement with Gavin et al. (11) and with this hypothesis, our results showed that
captopril could significantly attenuate the angiogenesis induced by exercise. In addition, we
were able to demonstrate that after chronic treatment with captopril (10 days), the VEGF
protein increases in skeletal muscle induced by exercise were completely blocked. In our
study, captopril did not have any effect on vessel density in sedentary or control animals.
The present study suggests a pathway where ANG II, acting through the AT1 receptor,
increases VEGF protein expression and consequently induces vessel growth. This hypothesis

was confirmed when the VEGF protein expression and angiogenesis were completely inhibited
after treatment with ACE inhibitor or AT1 receptor blocker. A recent report (32) has suggested a
complimentary pathway, where VEGF can induce ACE mRNA in cultured human umbilical vein
endothelial cells and thereby increase local ANG II production. Taken together, these results
suggest that a synergy between VEGF and ACE might play an important mechanism
underlying angiogenesis.
In summary, we confirmed the hypothesis that VEGF plays an important role in the
angiogenesis induced by short-term exercise training and that the expression of this growth
factor is partially controlled by the RAS. The effects described in this study should be
considered during treatments in which the blood supply to tissues is impaired and
neovascularization is a major therapeutic goal.
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